Be Bio Closes $130 Million Financing to Advance Engineered B Cells Platforms
Be Biopharma, cell therapy developer of Engineered B Cell Medicines (BeCM), has announced the closing of a $130 million financing, bringing the total investment in the Company to over $180 million. Proceeds will advance autologous and allogeneic Engineered B Cell Medicine (BeCM) platforms, as well as progress pipeline candidates in oncology and rare disease toward investigational new drug (IND) applications.
The Series B funding was led by ARCH Venture Partners and joined by new and existing investors including Bristol Myers Squib, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and Takeda Ventures.
Be Bio has a broad pipeline initially focused on rare disease and cancer. As the Company advances its platform, it plans to expand into additional therapeutic areas including infectious disease, neurological conditions and autoimmune disease.
Joanne Smith-Farrell, Ph.D., Chief Executive Officer at Be Bio said that the human B cell produces thousands of proteins per second. Be Bio is harnessing this remarkable cell to engineer a new class of cellular medicines that produce durable therapeutic proteins in vivo with the potential ability to dose titrate, and re-dose when required, without the need for toxic pre-conditioning.
With the support of highly regarded investors and the addition of Dr. Gillis to the Board of Directors, Be Bio is in a strong position to advance novel programs across rare disease and oncology portfolios, further develop the platform and manufacturing capabilities and expand team.
About Be Biopharma
Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.